18269803. NK CELL ENGAGER MOLECULES AND METHODS OF USE simplified abstract (REGENTS OF THE UNIVERSITY OF MINNESOTA)

NK CELL ENGAGER MOLECULES AND METHODS OF USE

Organization Name

REGENTS OF THE UNIVERSITY OF MINNESOTA

Inventor(s)

Martin Felices of Minneapolis MN (US)

Jeffrey S. Miller of Minneapolis MN (US)

Todd R. Lenvik of Minneapolis MN (US)

NK CELL ENGAGER MOLECULES AND METHODS OF USE - A simplified explanation of the abstract

This abstract first appeared for US patent application 18269803 titled 'NK CELL ENGAGER MOLECULES AND METHODS OF USE

The patent application describes a compound with an NK cell engaging domain linked to an IL-12-based polypeptide, which selectively binds to an NK cell and activates it.

• The compound includes an NK cell engaging domain and an IL-12-based polypeptide.
• The IL-12 polypeptide can be IL-12A, IL-12B, or both.
• The NK activating domain consists of IL-12A, IL-12B, and a flanking sequence linking the two.
• The compound may have a second NK activating domain and targeting domains.

Potential Applications: - Immunotherapy - Cancer treatment - Autoimmune disease treatment

Problems Solved: - Enhancing NK cell activity - Targeted therapy delivery

Benefits: - Improved immune response - Targeted treatment with reduced side effects

Commercial Applications: - Pharmaceutical companies for drug development - Biotechnology companies for research and development

Questions about the technology: 1. How does the compound specifically target NK cells? 2. What are the potential side effects of using this compound in therapy?

Frequently Updated Research: - Ongoing clinical trials testing the efficacy of the compound in cancer treatment.

Original Abstract Submitted

A compound generally includes an NK cell engaging domain operably linked to the NK cell engaging domain. The NK activating domain generally includes an IL-12-based polypeptide. The NK engaging domain selectively binds to an NK cell and an NK activating domain. In some embodiments, the IL-12 polypeptide can include an IL-12A polypeptide, an IL-12B polypeptide, or both an IL-12A polypeptide and an IL-12B polypeptide. In some embodiments, the NK activating domain includes an IL-12A polypeptide, an IL-12B polypeptide, and a flanking sequence linking the IL-12A polypeptide and the IL-12B polypeptide. In some embodiments, the compound can include a second NK activating domain. In some embodiments, the compound can include ones or more targeting domains.